Actuate Therapeutics: elraglusib Phase 2 meets primary endpoint; 1-year survival 43.6% vs 22.5% in mPDAC

ACTUATE THERAPEUTICS, INC.

1-year survival rate 43.6% in elraglusib+GnP arm vs 22.5% in GnP alone (p=0.002); median OS 9.3 vs 7.2 months (HR=0.63, p=0.016).
37% reduction in risk of death; ORR 27.7% vs 20.5%; multiple patients with complete/partial responses and 100% target lesion reduction.
Favorable safety profile; TEAEs and SAEs similar between arms; 2 patients with previously inoperable lesions successful resected.
Trial fully enrolled (286 patients); topline data expected 1H 2025; planned FDA engagement for Phase 3 registration trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.